Four people have been charged in the death of a 5-year-old boy who was killed inside a pressurized oxygen chamber at a ...

Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market rally that ...

Josh Brown, CEO of Ritholtz Wealth Management, said during a program on CNBC last month that he’s paying attention to Gilead Sciences Inc (NASDAQ:GILD).

El-Pukinson’s story is one of imagination, passion, and an unwavering pursuit of greatness. Born Puki Dauda Mohammed in ...

Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...

Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetesCATT1 Phase 3 trial expected to resume following ...

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of ...

Verified Market Research®, a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the RNA Therapeutics ...

The NSE Nifty 50 ended 0.33% lower at 22,397.20, while the BSE Sensex closed 0.27% down at 73,828.9 on Thursday.

awarding the drug breakthrough status. Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours ...

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was rejected for FDA approval, but the company thinks it now has a clear route to market with its patch product ...